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ABSTRACT 
Objective: Lower pregnancy rates have been reported in 
gonadotropin releasing hormone (GnRH) antagonist cycles 
in comparison to those with agonist cycles. A non-significant 
difference of 3.3% in the pregnancy rate per cycle in favour of 
GnRH agonists was found. The possible difference between these 
two protocols could be a limiting factor. We aim to determine if 
the embryos developed in long down-regulated assisted reproductive 
technology (ART) cycles differ from the ones obtained in antagonist 
cycles among women matched for age and follicle-stimulating 
hormone (FSH) administered on  cycle day 3.
Patients and Methods: Retrospective cohort analysis was done 
on a population from a  university affiliated hospital. 193 women 
undergoing standard in vitro fertilization (IVF) or intracytoplasmic 
sperm injection (ICSI) treatment were included. The age and 
cycle day 3 FSH matched women undergoing either long or short 
protocols were compared. Group A consisted of women who had 
long down-regulation with GnRH analogues, group  B consisted of 
women who had used GnRH antagonists. The clinical and ongoing 
pregnancy rates were compared. Day 3 embryo scores were 
compared between the groups.
Results: Although mean number of aspirated and inseminated 
oocytes were similar for  the groups and average embryo scores 
were comparable, clinical and ongoing pregnancy rates were 
higher in group A than in group B. The percentage of embryos 
with zero fragmentation and 8-10 blastomeres on day 3 was similar 
in antagonist and  long agonist cycles.
Conclusion: Long protocol ART cycles will result in 
comparable percentages of day 3 embryos with symmetric 8-10 
blastomeres with zero fragmentation to those in antagonist cycles.
Keywords: Gonadotropin releasing hormone agonist, Gonadotropin 
releasing hormone antagonist, Pregnancy, Embryo score, Day 3 
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ÖZET
Amaç: Gonadotropin salgılayıcı hormon (GnRH) antagonistlerinin 
kullanıldığı sikluslarda agonist sikluslarına göre daha düşük 
gebelik oranları bildirilmiştir. GnRH agonist sikluslarında anlamlı 
olmayan %3,3’ lük bir gebelik oranında artış vardır. Yaş ve üçüncü 
gün FSH değerleri eşleştirilmiş kadınlarda kısa ve uzun yardımcı 
üreme teknikleri (YÜT) sikluslarında embriyo gelişiminde farkın 
olup olmadığının araştırılması amaçlanmıştır.
Hastalar ve Yöntem: Universiteye bağlı  hastanenin YÜT 
merkezine başvuran 193 kadında retrospektif kohort analizi 
yapıldı. Yaş ve siklusun 3. günü serum folikül stimulan hormon 
(FSH) değeri benzer olan kısa ve uzun protokol ile klasik in vitro 
fertilizasyon (IVF) veya intrasitoplazmik sperm enjeksiyonu (ICSI) 
uygulanan hastalar dahil edildi. Group A, uzun GnRH analog 
protokolu, group B, ise kısa GnRh antagonist protokolü ile YÜT 
tedavisi aldı. Klinik ve devam eden gebelik oranları karşılaştırıldı. 
Üçüncü gün embriyo skorları gruplar arası karşılaştırıldı.  
Bulgular: Her iki grupta toplanan ve  insemine edilen yumurta 
sayısı ve ortalama embriyo skorları benzer olmasına rağmen 
klinik ve devam eden gebelik oranları grup A’da grup B’ye göre 
daha yüksekti. Sıfır fragmentasyon ve 8-10 blastomer olan 3. gün 
embriyo yüzdesi gruplar arası benzer idi. 
Sonuç: Uzun protokol YÜT tedavilerinde, kısa protokolde 
elde edilenlere benzer oranda 8-10 blastomerli, simetrik ve sıfır 
fragmentasyonlu 3. gün embriyoları görülmektedir.
Anahtar kelimeler: Gonadotropin salgılatıcı hormon agonisti, 
Gonadotropin salgılatıcı hormon antagonisti, Gebelik, Embryo 
skoru, 3.gün embryosu
Introduction
During the luteo-follicular transition  of the normal menstrual 
cycle, follicle-stimulating hormone (FSH) concentrations 
rise and surpass the threshold for stimulating a cohort of 
small antral follicles to grow [1]. Around the mid-follicular 
phase, the most mature follicle gains dominance over other 
follicles in the cohort  [2]. This dominant follicle continues 
Does the quality of an embryo  differ between long down-regulated 
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its growth despite  decreasing FSH concentrations [3], 
whereas the remaining follicles from the  recurited cohort 
become atresic, due to insufficient stimulation by FSH. 
This decreasing FSH level and mild ovarian stimulation 
with subsequent closure of the FSH ‘gate’ or ‘window’ [4] 
appears to be essential for the selection of a single dominant 
follicle. Multifollicular growth is established in current in 
vitro fertilisation (IVF) protocols by generating FSH serum 
concentrations far above the threshold for an extended 
period starting in the early follicular phase. 
Conventional ovarian stimulation protocols aim to 
stimulate growth of many follicles in order to obtain multiple 
oocytes for IVF and thus multiple embryos allowing for 
the selection of several for transfer [5]. Preceding the 
administration of high doses of gonadotropins, pituitary 
down regulation is normally achieved by prolonged 
administration of agonists of the gonadotropin releasing 
hormone  (GnRH). This is the “long protocol” . Increasing 
knowledge about the physiology of ovarian follicle 
development and selection of the dominant follicle [1,6], 
together with the clinical introduction of GnRH antagonists 
in IVF [7, 8] allows ovarian stimulation to be commenced 
in an undisturbed menstrual cycle.  GnRH antagonists have 
emerged as an alternative approach to prevent surges of 
luteinizing hormone (LH) [9].
Decreases in serum estradiol (E2) levels and related rates 
of implantation have been reported for cycles stimulated  by 
a GnRH antagonist [10] suggesting that there is an adverse 
effect of GnRH antagonists on either oocyte quality, embryo 
development, or the endometrium [11]. Concerns have been 
raised regarding the possibility of direct effects of GnRH 
antagonists on the endometrium [12], and on  altered patterns 
of follicular development [13].
In this study, we  determined if day 3 embryo scores and 
assisted reproductive technology (ART) outcomes of the 
standard long GnRH agonist protocol for ovarian stimulation 
differed from those of the GnRH antagonist protocol.
Patients and Methods
One hundred and ninety-three women undergoing IVF cycles 
at the ART Unit of a University affiliated Hospital, were 
selected for retrospective cohort analysis. All women were 
under the age of 38 years. The women were placed in two 
groups according to the ART protocol. Group A consisted of 
women for whom the long agonist protocol was used,  group 
B consisted of women for whom the antagonist protocol was 
used. All practices and protocols conformed to the ethical 
requirements for assisted reproductive technology programs of 
the Ethics Commitee of the institution and conformed to the 
provisions of the Declaration of Helsinki. 
Hormonal Stimulation
Two controlled ovarian hyperstimulation protocols were 
chosen. For the long protocols, pituitary desensitization was 
achieved by s.c. administration of leuprolide acetate (1 mg/
mL; Lucrin flacon , Abbott) during the luteal phase of the 
cycle preceding before the start of gonadotropin stimulation 
[14]. When adequate down regulation had been achieved 
(endometrial thickness <4 mm or serum estradiol <50 pg/
ml), usually after at least 10 days of leuprolide acetate 
administration, controlled ovarian hyperstimulation was 
accomplished with s.c. administration of recombinant FSH 
(Gonal-F, Follitropin alpha; Merck-Serono Inc.),  at a starting 
dose of  300 IU per day. For the short protocol, the starting 
dose of gonadotropin  was  400 IU per day of cetrorelix 
acetate (Cetrotide, Merck-Serono Inc), which was started 
on cycle day 6.  Dose adjustments were individualized after 
5 days of ovarian stimulation. Follicular monitoring was 
performed by using  a Toshiba SAL 77B machine (Toshiba, 
Tokyo, Japan). Ten thousand IU of human chorionic 
gonadotropin ((hCG)), 10,000 IU (Profasi Merck-Serono 
Inc.) was administered when at least one follicle had a mean 
diameter of 18 mm. Both the analogues and the antagonists 
were continued till the day of hCG injection.
Oocyte Retrieval, Insemination, Embryo Culture, and 
Grading
Oocytes were retrieved transvaginally 35 or 36 hours after 
hCG injection. The decision to perform standard IVF or ICSI 
had been  based on a diagnosis of infertility.  For cleavage-
stage embryo transfer, embryos were cultured in P1 medium 
(Irvine Scientific, Santa Ana, CA). The scoring system 
of Women and Infants Hospital (WIH) was used for the 
selection of day 3 embryos [15]. Individual WIH scores for 
each embryo were calculated as the sum of “development+ 
fragmentation+symmetry”. The average embryo score was 
recorded for each transferred  day 3 embryo. Embryos 
were transferred at the cleavage-stage by using a Wallace 
(Cooper Surgical, Shelton, CT) or Embryon catheter (Sage 
BioPharma, Bedminster, NJ).  Embryos were transferred 
under transabdominal ultrasonographic guidance using a 
Toshiba SAL 77B machine (Toshiba, Tokyo, Japan). 
-HCG titers were drawn 14 days after retrieval and if 
positive were repeated 2 days later. In patients with a 
doubling of the -hCG value, transvaginal ultrasonography 
was used 4 weeks after retrieval to  find evidence  of a sac 
to confirm clinical pregnancy. Luteal support consisted of 
daily use of transvaginal progesterone gel (Crinone 8%; 
Merck-Serono Inc.) through the 10th week of gestation. 
Statistical Evaluation
All analyses used StataSE 10.0 (Statacorp, College Station, 
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Texas, USA). For the whole group statistical evaluation 
Student’s t-test was used; p<0.05 was considered significant. 
In order to detect the difference between clinical pregnancy 
rates of 50% and 25%, 145 and 45 patients were needed in 
two arms for a calculation accepting type I error as 0.05 
with the power of 81%. Likewise, 145 and 45 patients were 
needed in two arms for  a calculation accepting type I error as 
0.05 with the power of 73% in order to detect the difference 
between ongoing pregnancy rates of 42% and 20%. 
Results
There were 148 women in group A and 45 in group B. The 
mean age and body mass index (BMI) and serum level of 
FSH on cycle day 3 were similar between the groups. The 
duration of gonadotropin stimulation was comparable 
between groups. Although the starting dose and the total 
dose of gonadotropin was higher in group B than in group A 
the mean serum estradiol level on the day of hCG injection 
was lower in group B than  in group A. However,  the mean 
estradiol level per oocyte retrieved was comparable between 
the groups  (Table I). 
The mean number of total oocytes and of mature oocytes 
were comparable between the groups. Likewise,  the mean 
number of fertilized oocytes and of embryos with more 
than 6 cells on day 3 were comparable between the groups. 
Similarly,  average scores of the transfered embryos were 
comparable in group A and group B (Table I).   
Clinical pregnancy rates per cleavage stage transfer were 
higher in group A than in group B. Accordingly,  there were 
more ongoing  pregnancies per cleavage stage transfer in 
group A than in group B (Table I). 
The percentage of embryos with zero fragmentation on 
day 3 was higher in group B than  in group A so were the 
percentage of embryos with symmetric blastomeres (Table II). 
Discussion
Given the close correlation between the number of embryos 
from which to select and the chances of pregnancy [5], 
pregnancy rates may suffer from stimulation protocols where a 
lower  number of good quality embryos are obtained. Tarlatzis 
et al. [16] and Tan et al. [17] have shown higher implantation 
and pregnancy rates with the long GnRH analogue protocol. 
This has been attributed to more effective LH suppression, 
higher oocyte retrievals per cycle, and more embryos 
developed. The clinical introduction of GnRH antagonists 
facilitated the development of new approaches to ovarian 
(hyper) stimulation in IVF. As the action of GnRH antagonists 
is characterized by an immediate suppression of pituitary 
gonadotropin release, treatment can be limited to the days 
in the mid-to-late follicular phase to prevent a premature LH 
rise. These compounds offer an opportunity to start   the IVF 
treatment within an undisturbed menstrual cycle.
As result of multifollicular growth, hormone levels of 
estradiol are increased in the late follicular phase. The effects 
of these supraphysiological hormone concentrations on 
follicle- and oocyte quality remain unclear [6]. The potential 
detrimental effect of ovarian hyperstimulation on endometrial 
receptivity and  the negative influence of endometrial changes 
on embryo implantation have all been investigated [6, 18,19]. 
In our study, both groups had maximum E2 levels below 
2000 pg/ml; this was lower than the levels mentioned in the 
literature [20]. Mean E2 levels at the late follicular phase 
between 2,800 and 4,500 pmol/l (conversion factor 3.671) do 
not represent clinically important differences in the ovarian 
response [21,22].  In our study,  the mean E2 levels on the day 
of hCG administration were higher than these ranges. Hence, 
the ovarian response in our groups were neither high  nor poor. 
These (physiologic) hormone concentrations at the follicular 
phase probably resulted in a similar number of mature oocytes. 
Good quality oocytes lead to better embryos, which is a 
predictive factor for pregnancy [23]. In our study, the chance 
of subsequently producing good quality embryos was similar 
for the  protocol using the long stimulation with GnRH agonist 
and the protocol using the GnRH antagonist. Both protocols 
resulted in comparable number of mature oocytes, which are 
likely to   result in good quality of embryos. 
Women who respond poorly or not at all to standard 
controlled ovarian hyperstimulation treatments are referred 
to as ‘low, or poor responders’. Numerous criteria have been 
proposed to characterize a poor response. The number of 
developed follicles and/or the number of oocytes are two of the 
most important criteria for defining a poor ovarian response 
[24].  The proposed number ranges from less than three to less 
than five dominant follicles on the day of hCG administration 
[5-8], and/or less than three to less than five retrieved oocytes 
[25 ]. Both the number of follicles and a peak estradiol value 
of <300 pg/ml during ovarian stimulation are also used in 
defining  a poor response. None of the patients in our study 
groups fulfilled these latter  criteria. Hence,  the women in our 
study did not have  a low ovarian reserve.
Although,  embryo quality is not the only factor 
determining implantation rate, embryo score is predictive of 
pregnancy [26]. Since day 3 embryos with more than 6 cells 
and the average scores of embryos transfered at cleavage 
stage were comparable in both groups, similar   pregnancy 
rates would have been expected. Comparison of implantation 
rates between different protocols have led to the belief that 
the beneficial effects of GnRH analogues were related to an 
improved endometrial receptivity [14]. However, a direct 
action of GnRH analogue on the endometrium remains 
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speculative. Since,  LH/hCG receptors have been recognized 
in the endometrium level [27,28], another way for an GnRH 
analogue  to influence uterine receptivity might be through 
the reduction of gonadotropin synthesis, with subsequent 
consequences on endometrial LH receptor function. Lower 
pregnancy rates associated with GnRH antagonist use [7, 
29] have been reported. Even though a non-significant 
difference of 3.3% in the pregnancy rate per cycle in favour 
of GnRH agonists was given, our results showed a significant 
difference both in clinical and ongoing pregnany rates.
Ovarian sensitivity to FSH is regulated by intra-ovarian 
factors, like FSH receptor inhibitors [30] and growth factors 
[31]. Growth factors act in an auto- or paracrine fashion 
through their specific receptors. Within cells, their signal 
transduction pathways merge with the FSH-activated pathways 
and subsequently modulate FSH stimulated responses within 
the cell. Numerous growth factors have been identified which 
contribute to this regulation of normal ovarian function. In 
our study, the morphology of the embryo on the third day 
in each group was similar. There were more embryos with 
zero fragmentation in the antagonist group. However,  this 
non-significant difference together with the non-significant 
increased percentage of day 3 embryos with symmetric 
blastomeres did not conclude to  favourable pregnancy rates.
One of the limitations of our study could be the difference 
in both the starting and the total doses of gonadotropins in the 
two groups. However,  the level of serum estradiol per oocyte 
collected was similar for  the two groups. Hence,  the effect of 
gonadotropins on the ovaries could be accepted as identical. 
Moreover,  the number of retrieved, fertilized  oocytes  were 
almost the same. The embryo gradings of the transferred 
embryos were also similar. Our primary outcome measure was 
to determine whether  the embryos developed in long down-
regulated ART cycles differed  from the ones obtained in 
antagonist cycles for women matched for  age and FSH levels 
on day 3. Thus, other confounding factors which would affect 
implantation have not been investigated.  These might be due 
to more suppression of GnRH antagonists on the endometrium 
than that expected with GnRH agonists.
We have shown that women younger than 38 years  of age 
are very likely to obtain higher pregnancy rates with long GnRH 
analogue cycles than with antagonist cycles if the duration of 
stimulation is shorter than 12 days.  The women seem to have 
one more frozen embryo on average after long GnRH analogue 
protocol than the women with antagonist protocol. This will 
probably increase the chance for subsequent pregnancies 
obtained from frozen-thawed embryo transfers. Even though 
cycle characteristics closely resemble one another and the day 
3 embryo characteristics are almost similar, more pregnancies 
are achieved with long GnRH analogues.  The endometrial 
receptivity should be well-evaluated before embryo transfer 
and if needed, then embryos should be frozen for future natural 
cycle with thawed embryo transfer treatments. 
Table I. The patient demographics of the study groups
Group A 
(n=148)
Group B 
(n=45) p value
Mean age 
(years)
34.62
(33.90 - 35.34)
36.09
(34.79 –37.39) 0.05
Body mass 
index (kg/m2)
26.84
(25.29 – 28.38)
25.29
(23.11 –27.47) 0.33
Cycle day 3 
FSH (mIU/ml)
7.00
(6.56 – 7.44)
7.20
(6.38 - 8.02) 0.67
Duration of  
stimulation with 
gonadotropin 
(days)
11.52
(10.40 - 11.64)
11.71
(11.47 - 11.96) 0.14
Gonadotropin 
start dose (IU)
322.80
(304.02 – 341.59)
443.33
(402.34 – 
484.33)
0.0001
Total 
gonadotropin 
dose (IU)
3662.76
(3421.80-
3903.71)
   5355.68
(4844.48 
–5866.89)
0.0001
Mean estradiol 
level on hCG 
day  (pg/ml)
1666.33
(1508.48-
1824.18)
1227.05
(957.52-
1496.57)
0.01
Mean estradiol 
level per oocyte 
collected (pg/
ml)
172.63
(157.79-187.48)
170.02
(128.61- 
211.43)
0.94
Mean number 
of aspirated 
oocytes per 
retrieval
11.01
(9.93-12.10)
9.26
(7.05- 11.46) 0.13
Mean number of 
inseminated 
oocytes per 
retrieval
10.24
(9.22 - 11.27)
8.67
(6.74 – 10.60) 0.15
Mean number 
of  fertilized 
oocytes per 
retrieval
7.63
(6.77- 8.50)
6.26
(4.58 – 7.95) 0.14
Mean number 
of embryos 
with  >6 cells by 
day 3
4.44
(3.80 -  5.08)
3.89
(2.42 - 5.36) 0.46
Number of 
embryos frozen 
on day 3
2.32
(1.83 - 2.81)
1.23
(0.49 -1.96) 0.03
Average 
WIH score 
of embryos 
transferred on 
day 3 *
6.61
(6.41 - 6.83)
6.18
(5.77 - 6.60) 0.06
Mean number 
of embryos 
transferred on 
day 3 
3.50
(3.34- 3.65)
3.81
(3.48- 4.14) 0.07
Implantation 
rate 
21.11
(15.03 – 25.20)
5.83
(0.4- 12.08) 0.01
Clinical 
pregnancy per 
day 3 transfer 
(%)
50.00
(41.85 – 58.15)
22.22
(9.59 – 34.85) 0.001
Ongoing 
pregnancy per 
day 3 transfer 
(%)
40.30
(31.89 – 48.71)
20.75
(1.74 – 22.65) 0.001
All values are given as mean and 95% confidence intervals (CI) 
in parentheses, p< 0.05 is statistically significant, * The sum of 
“development+ fragmentation+symmetry”of each embryo transfered 
divided by number
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